A：The company is transitioning to publishing an annual shareholder letter and will continue to provide regular updates through a quarterly earnings call, earnings release, and supplemental materials.

A：Key areas of progress include the U.S. business poised for acceleration, global scale creating a competitive advantage, deepening customer relationships, and investments in data and technology infrastructure.

A：The company announced a strategic shift in the weight loss business to focus on providing customers with access to the broadest possible assortment of innovative medications, alongside comprehensive clinical care and lifestyle support.

A：Hims and Hers' provider network can now send prescriptions for specific medications to the Lily Direct Pharmacy and access self-pay pricing for Hims and hers customers.

A：Hims and Hers is rapidly becoming the world's largest consumer health platform, with planned acquisitions such as Eucalyptus to extend its leadership in consumer health across multiple countries.

A：The platform is providing customers with access to higher quality care, easier to replicate, and helping them build long-term daily health routines, motivated by the desire to stay healthy rather than just get healthy.

A：The three key areas of focus are evolving the existing operating system for comprehensive end-to-end care, embedding intelligence at every step of the care journey, and supporting the closed loop proprietary data flywheel.

A：The platform is being re-architected around reusable modular capabilities, which allows it to scale efficiently across new conditions, categories, and geographic regions. This enables the company to launch new offerings more quickly and supports a more approachable customer and provider experience.

A：The stack includes a new no code commercial engine, configurable clinical workflows, a modernized mobile and messaging experience, and a complete view of each customer's health journey.

A：AI is used to increase the quality of care by producing responses informed by the full patient context, and it is embedded at every step of the care journey. An example is an AI tool that assists care coaches and interacts with patients, while another is Labs AI, which explains biomarker results and recommends when to escalate to a provider.

A：Independent providers review, correct, and approve AI inputs, generating clinician-verified training signals for the models. This provides the highest quality label in AI, which cannot be acquired otherwise.

A：The flywheel integrates consumer intake and diagnosis, treatment journey, decisions, and outcomes in a single stack, strengthening the company's insights and allowing the platform to learn and improve continuously.

A：The company's global scale enables a force multiplier effect with models reflecting diverse populations, enhancing the intelligence of the platform. Integration of providers, protocols, and regulatory infrastructure sets the company apart from traditional EHR systems and allows for unified care models.

A：The company is building a platform with an intelligence layer that personalizes every step of the customer experience and a trust architecture that earns the right to operate in healthcare. This is aimed at becoming the preferred platform for customers and partners.

A：The company has made a strategic pivot within the weight loss specialty to prioritize branded products, which has led to an expansion of the market and significant new subscriber additions. This pivot resulted in the discontinuation of prioritizing compounding products. Early signs indicate high subscriber engagement, and the company expects this to be transformational for the platform, impacting revenue, and margins positively. The company is focused on accelerating growth, establishing a leadership position, and maintaining discipline to ensure continued healthy free cash flow.

A：The company plans to continue investing in technology, with a focus on enhancing its infrastructure to roll out new features and offerings. Additionally, they aim to invest in specialized technology and engineering talent to improve insights across the consumer journey and make operational investments for expansion into new specialties and to decrease costs.

A：The company expects these investments to be financially accretive in the mid to long term, with signs of success already appearing in the near term. Shorter-term investments are focused on operational capabilities to expand into new specialties and reduce costs.

A：Trust remains a cornerstone of the Hems and hers brand and will continue to guide new specialty expansion, which will follow a compliance and consumer-centric framework to ensure quality and safety standards.

A：The company's primary financial objective is to grow the business while ensuring strong free cash flow, which allows for swift action on market opportunities and the potential for strategic pivots impacting GAAP financials.

A：The company prioritizes strong growth in cash flow generation. In the first quarter, they generated $89 million from operations and $53 million in free cash flow, with an acquisition contributing to their strategy to add more subscribers to the platform.

A：Investments in the upcoming quarters will focus on strategic growth levers, including expanding into new specialties, using technology to elevate care quality, broadening access to personalized care, leveraging partnerships for best-in-class health services, and expanding internationally.

A：The Eucalyptus acquisition is expected to close in the second half of the year and will expand the company's ability to enhance the consumer experience in several additional markets. It is also expected to allow the company to invest in emerging markets that can become future profit centers.

A：For the second quarter, the company anticipates revenue between $680 and $700 million, a year-over-year increase of 25% to 28%, and adjusted EBITDA between $35 and $55 million. The full-year outlook has been raised to revenue between $2.8 to $3 billion, with adjusted EBITDA between $275 and $350 million. The adjusted EBITDA margin is expected to be around 11% at the midpoint of these ranges.

A：The expectations for AI initiatives include the development of multiple agents that support each stage of the customer's journey across every specialty served, making the intake process dynamic, clinical decisions more informed, and providing ongoing care and support for managing health.

A：Recent tech leadership changes at Hins are seen as an indication that they recognize Hins' platform with massive scale, unique data, infrastructure, and customer trust, which is necessary to leverage the breakthrough in technology.

A：The company views its differentiation and competitive advantage in the peptide strategy through its large compounding footprint allowing for personalized dosing at scale, a fully verticalized US supply chain for quality and reliability, investments in clinical experts and lab testing for product development, and its position to deliver the category safely and appropriately.

A：Investments made to support the peptide category strategy include a focus on having a best-in-class position rather than being first to market, developing a first-class oversight and safe supply chain, investing in infrastructure and capabilities, and actively working on data transparency, validated supply chains, and clinical protocols.

A：Since the 'no deal' went live, there has been a transition from compounded to branded products for Jipone subscribers, with the retention through this transition being closely monitored. The exact portion of subscribers who have made this transition and the retention levels are mentioned as part of the company's response, but specific figures are not provided in the transcript.

A：The company's strategic approach to the peptide category is to ensure it is best in market rather than just being first to market. Key preparations include data transparency, validated supply chains, and clinical protocols. While the company is actively preparing for potential reclassification, it is not clear how soon this will happen, with more information expected by the end of the year.

A：The company is actively assessing the opportunity internally relative to other specialties, focusing on being 'best in market' when entering the peptide category. They are investing in data transparency, validated supply chains, and clinical protocols to ensure a successful and sustainable market entry.

A：Gross margin volatility is expected as part of the strategic pivot, with a degradation of over a few points in the coming quarters. The company plans to address these pressures by focusing on becoming the default health and wellness provider in the U.S., establishing leadership, and leveraging that to drive economies of scale and pass value back to consumers. Additionally, the focus is on continuing strong cash flow out of domestic operations for reinvestment globally to follow the same playbook.

A：The EBITDA margin in the back half of the year is expected to be supported by the weight loss transition, new consumers on monthly cadences instead of quarterly, and leveraging G&A expenses. There's also an expectation of marketing efficiency, stronger cross-selling, low acquisition channel throughput, and improved retention patterns. These factors, combined with the investment made in the front half of the year, give high conviction to the ability to continue to compound EBITDA dollars.

A：The company is focusing on establishing a leadership position in the U.S. and globally by investing to leverage technology and rich data sets to pass value back to consumers. This strategy is reflected in revenue guidance with the aim of taking revenue up while maintaining flexibility on EBITDA to capture opportunities. Gross margin dynamics will continue to be provided for visibility, but the financial equation for the company remains focused on driving strong absolute EBITDA dollars and controlling cash flow generation while establishing the leadership position.

A：AI is expected to change the user experience by building a multi-agent model that personalizes and optimizes the customer journey, resulting in better outcomes for patients. This will include faster responses, more personalized dosing, and recommendations on care, as well as enhanced engagement experiences post-consultation. The goal is to achieve higher long-term retention, better engagement rates, and the potential to offer a 'second opinion' through the data layer, which can provide 1000 opinions simultaneously. The company is also exploring both building its own devices and partnering with existing players in the ecosystem for wearables.

A：The company is evaluating both creating its own wearable devices and partnering with existing players in the ecosystem. The strategy is to be universal, allowing seamless integration with existing devices that patients may prefer, so that the data can be leveraged to improve care. The company's team is uniquely capable of designing world-class hardware experiences, which could be incorporated into different membership tiers to enrich the engagement with the platform.

A：The branded side of the business is expected to build awareness for innovative categories and scale growth for specific treatments, thereby contributing to the company's growth. The company's ability to leverage geographic footprints and relationships with consumers makes it a powerful partner for pharma, biotech, devices, and diagnostics companies seeking distribution. The focus is on building trust with consumers as curators of high-quality everyday care and working with innovators to bring great products to scale. The company is in discussions with several partners in these areas.

A：The focus in the U.S. is on scaling categories such as labs, menopause, and testosterone quickly to establish a leadership position. With this scale, the ability to drive higher margins over time is expected. While the focus is on subscriber base growth and share expansion, investment may vary based on opportunities that show signs of progress. The overall strategy is to continue to build a leadership position, drive economies of scale, and ensure that these efforts enable the generation of healthy free cash flow.

A：The new categories mentioned are primarily focused on the domestic market with category learning taking place domestically. However, there are some established branded pharmaceutical manufacturers in international markets with longer relationships, which are seeing model adoption. The categories like labs, menopause, and testosterone will start in the U.S. and then expand to critical international regions. The company expects strong U.S. growth due to strategic pivots and clear revenue recognition dynamics, and also anticipates international growth, which, when combined, are expected to contribute to the revenue growth guidance for the remainder of the year.